Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P30874

UPID:
SSR2_HUMAN

ALTERNATIVE NAMES:
SRIF-1

ALTERNATIVE UPACC:
P30874; A8K3Y0; B2R9P7; Q4VBP0; Q96GE0; Q96TF2; Q9BWH1

BACKGROUND:
The Somatostatin receptor type 2, known alternatively as SRIF-1, is integral to the somatostatin signaling pathway, affecting adenylyl cyclase activity, calcium channel function, and MAPK phosphorylation. It serves as the primary somatostatin receptor in pancreatic alpha- and beta-cells, influencing hormone secretion and cell growth, and plays a role in neuronal migration and axon outgrowth.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Somatostatin receptor type 2 offers a promising avenue for developing novel treatments. Its regulatory effects on hormone secretion, cell proliferation, and neuronal development highlight its potential as a therapeutic target in addressing diseases related to endocrine function, cancer, and neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.